Group 1: Hotel Industry Insights - The hotel industry is entering a new phase characterized by non-linear growth among leading players, driven by expectations of cyclical turning points and capital consolidation, with a long-term focus on scale and efficiency [17][18] - The valuation of hotels follows a three-dimensional framework: macro supply-demand mismatches determine valuation turning points, structural upgrades amplify volatility, and individual company cycles provide alpha opportunities [17] - The current cycle's bottom is marked by increased differentiation within the industry, with leading hotels expected to see RevPAR (Revenue per Available Room) recover as supply stabilizes and demand rebounds, particularly in leisure travel [17][18] Group 2: Social Services Sector - The social services sector has seen a 1.52% increase during the reporting period, outperforming the broader market by 2.71 percentage points, with notable stocks including Tongdao Liepin and Keri International [19][20] - The sector is actively responding to the silver economy, with policies promoting the development of elderly care services and companies like New Oriental launching local interest courses for retirees [21] - The Spring Festival is expected to drive significant travel demand, with predictions of approximately 95 million air passengers during the holiday period, indicating a strong recovery in travel-related services [21] Group 3: Food and Beverage Sector - The food and beverage sector has experienced a decline of 1.37%, with A-share food and beverage indices falling by 1.57%, while H-share indices showed a slight increase [26] - The sector is characterized by differentiated performance, with alcoholic beverages, particularly baijiu, showing stable prices and a focus on demand recovery during the Spring Festival [27] - Recommendations include leading companies in various categories, such as Moutai for baijiu, Yili for dairy, and Nongfu Spring for beverages, highlighting their strong growth potential and market positioning [27][28] Group 4: Pharmaceutical Industry - The pharmaceutical industry is witnessing a robust outflow of innovative drugs and a recovery in the CXO sector, driven by favorable clinical data and supportive policies [33][34] - The domestic supply-demand landscape remains stable, with a focus on innovative drug forms and technologies such as AI in healthcare and brain-machine interfaces, which are expected to see significant growth [35] - Investment recommendations include companies with strong competitive advantages in innovation and cost control, such as Mindray Medical and WuXi AppTec [35][36]

Investment Rating - The report maintains an "Outperform" rating for the pharmaceutical and biotechnology sector [5] Core Views - The pharmaceutical sector underperformed the overall market, with a 0.39% decline in the biopharmaceutical sector compared to a 1.17% increase in the overall A-share market [32] - The TTM price-to-earnings ratio for the pharmaceutical sector is 38.51x, which is at the 84.35 percentile of the historical valuation over the past five years [32][37] Summary by Sections Market Performance - The overall A-share market increased by 1.17%, while the Shanghai and Shenzhen 300 index decreased by 0.62%. The biopharmaceutical sector saw a decline of 0.39% [32] - Among sub-sectors, chemical pharmaceuticals fell by 1.11%, while medical services dropped by 2.17%. Conversely, medical commercial and traditional Chinese medicine sectors saw increases of 4.26% and 0.89%, respectively [32] Fund Holdings Analysis - As of Q4 2025, the net asset value of pharmaceutical funds reached 358.4 billion, a decrease of 9.0% from the previous quarter [11] - The proportion of pharmaceutical holdings in all funds was 7.97%, down by 1.71 percentage points [16] - The largest sub-sectors by holdings were chemical preparations (37.5%) and other biological products (20.8%) [19] Key Company Earnings Forecasts and Investment Ratings - Major companies such as Mindray Medical (237 billion market cap, outperform rating), WuXi AppTec (293.6 billion market cap, outperform rating), and Aier Eye Hospital (105.4 billion market cap, outperform rating) are highlighted for their strong earnings forecasts [4] - The report lists several companies with outperform ratings, including New Industry, Huatai Medical, and others, with projected earnings growth over the next few years [4] Investment Strategy - The report emphasizes the importance of the CXO sector and recommends focusing on investment opportunities within this area due to its competitive advantages [41] - It also suggests continued recommendations for innovative drugs and the associated industry chain, with a specific investment portfolio for January 2026 including companies like Mindray Medical and WuXi AppTec [42][43]

Core Insights - The report emphasizes the importance of innovation in the pharmaceutical and biotechnology industry, particularly focusing on the overseas expansion of innovative drugs and the adoption of new technologies [1][4]. - The investment rating for the sector is maintained at "outperform the market" [2]. Group 1: Market Overview and Trends - The overseas market for innovative drugs and the CXO industry is expected to perform exceptionally well in 2025, driven by continuous business development (BD) activities, strong clinical data, and supportive policies [4]. - The domestic supply and demand remain stable, with a shift in payment systems favoring innovation. National health expenditure increased by 4.7% year-on-year in the first 11 months of 2025, marking a recovery after two years of decline [4]. - The report highlights the significant growth potential in new drug forms such as dual antibodies and small nucleic acid drugs, as well as innovations in AI healthcare and brain-machine interfaces [4]. Group 2: Investment Recommendations - The report recommends focusing on companies with global competitiveness and differentiated innovation capabilities, as well as domestic CXO leaders with high barriers in cost control, technology accumulation, and production capacity [4]. - Recommended stocks include Mindray Medical, WuXi AppTec, Kelaiying, Aier Eye Hospital, and several others, with specific mention of H-shares like Kelun-Bio and CanSino Biologics [4][5]. Group 3: Financial Performance and Projections - The report provides a detailed strategy portfolio for 2026, listing companies along with their projected net profits and price-to-earnings (PE) ratios, indicating a generally positive outlook for the sector [5]. - The pharmaceutical sector's overall performance in 2025 was strong, with significant gains in sub-sectors such as medical services and chemical pharmaceuticals, driven by BD collaborations and clinical data releases [12][23]. Group 4: Fund Holdings and Market Sentiment - As of Q4 2025, the net asset value of pharmaceutical funds decreased by 9.0%, with a notable shift where passive funds surpassed active funds for the first time since 2019 [25][32]. - The report indicates a decline in the proportion of pharmaceutical holdings in both active and non-pharmaceutical funds, with a concentration in chemical preparations and other biological products [32][40].

Group 1 - The core conclusion indicates that in the third week of January, there was a net outflow of funds totaling 170.5 billion yuan, compared to an inflow of 4.9 billion yuan in the previous week [1][7] - Short-term sentiment indicators are at a high level since 2005, while long-term sentiment indicators are at a mid-low level since 2005 [1][11] - From an industry perspective, the highest transaction volume share in the past week was in the semiconductor (100%), electronics (99%), and defense industries (99%) [2][13] Group 2 - In the second week of January, the financing balance decreased by 8.3 billion yuan, public fund issuance increased by 39.3 billion yuan, ETF net redemptions were 162.3 billion yuan, and northbound capital estimated net outflow was 9.3 billion yuan [1][7] - The highest financing transaction share was in the machinery equipment (89%), electric power equipment (74%), and textile and apparel (79%) industries, while the lowest was in banking (12%), oil and petrochemicals (17%), and real estate (21%) [2][13]

Investment Rating - The investment rating for the company is "Outperform the Market" (maintained) [1][6][22] Core Viewpoints - The management's recent share buybacks demonstrate confidence in the company's future and stock price [3][4] - The company's new product series, PUCKY and Starry People, have shown strong demand, with sold-out status on official platforms and significant price premiums on secondary markets, indicating potential for IP value enhancement during the upcoming holiday season [3][5] - The company is expected to see substantial profit growth, with projected net profits for 2025-2027 at 120.2 billion, 170.5 billion, and 208.9 billion respectively, reflecting year-on-year growth of 284.4%, 41.9%, and 22.6% [3][10][15] Summary by Relevant Sections Share Buyback - The company announced a buyback of 500,000 shares at a price of 192.97 yuan per share and the cancellation of 1.4 million shares at 179.60 yuan per share, indicating a total buyback amount of approximately 347.9 million yuan [2][5] Product Performance - Recent trends show that the PUCKY and Starry People series have sold out on official websites, with price premiums on secondary markets ranging from 2-3 times for hidden versions and 70-200% for regular versions, suggesting strong market demand [3][5][9] Financial Projections - The company has revised its profit forecasts, expecting revenues of 356.2 billion, 512.5 billion, and 634.5 billion for 2025-2027, with corresponding year-on-year growth rates of 173.2%, 43.9%, and 23.8% [10][19] - The gross margin is projected to exceed 70% in the first half of 2025, with a steady gross margin of around 71% expected through 2027 [12][19]

Investment Rating - The investment rating for the company is "Outperform the Market" (maintained) [1][6][3] Core Views - The management's recent share buybacks demonstrate confidence in the company's future and stock price [4][3] - The company's new product series, PUCKY and Starry People, have sold out on official platforms and are trading at significant premiums on secondary markets, indicating strong IP potential [3][5] - The company is expected to see substantial profit growth, with net profits projected to reach 12.02 billion, 17.05 billion, and 20.89 billion for 2025-2027, reflecting year-on-year growth of 284.4%, 41.9%, and 22.6% respectively [3][10] Summary by Sections Share Buyback - The company announced a buyback of 500,000 shares at a price of 192.97 yuan per share and the cancellation of 1.4 million shares at 179.60 yuan per share, showing a total buyback of 3.47 billion yuan for 1.9 million shares [2][5] Product Performance - Recent trends show that the PUCKY and Starry People series have sold out on the official website, with hidden versions trading at premiums of 2-3 times and regular versions at 70-200% premiums [5][9] Financial Projections - The company has revised its profit forecasts, expecting net profits of 12.02 billion, 17.05 billion, and 20.89 billion for 2025-2027, with corresponding P/E ratios of 23, 16, and 13 [3][10] - Revenue projections for 2025-2027 are set at 35.62 billion, 51.25 billion, and 63.45 billion, with growth rates of 173.2%, 43.9%, and 23.8% respectively [10][19]

Investment Rating - The report maintains an "Outperform" rating for the pharmaceutical and biotechnology sector [5][41]. Core Views - The pharmaceutical sector has shown weaker performance compared to the overall market, with a TTM P/E ratio of 38.51x, which is at the 84.35th percentile of the past five years [1][37]. - The report highlights the importance of the CXO sector, emphasizing the competitive advantages of Chinese companies in the chemical CDMO field, and suggests that the sector's valuation is expected to recover [41]. - The report recommends focusing on innovative drugs and the associated industry chain, with a notable mention of the upcoming JPM conference and the clinical progress of innovative drugs overseas [41][42]. Summary by Sections Market Performance - The overall A-share market increased by 1.17%, while the biotechnology sector declined by 0.39%. The medical services sector was the worst performer, dropping by 2.17% [1][32]. - The report notes that the largest sub-sectors by holding percentage are chemical preparations (37.5%) and other biological products (20.8%) [19]. Fund Holdings Analysis - As of Q4 2025, the total net asset value of pharmaceutical funds reached 358.4 billion, a decrease of 9.0% from the previous quarter [11]. - The report indicates that the pharmaceutical holdings of all funds accounted for 7.97%, down by 1.71 percentage points [16]. Key Company Earnings Forecasts - The report provides earnings forecasts for several key companies, all rated "Outperform": - Mindray Medical (300760.SZ): 2024A net profit of 11.67 billion [4] - WuXi AppTec (603259.SH): 2024A net profit of 9.35 billion [4] - Aier Eye Hospital (300015.SZ): 2024A net profit of 3.56 billion [4] - New Industry (300832.SZ): 2024A net profit of 1.83 billion [4] - Huatai Medical (688617.SH): 2024A net profit of 670 million [4] Investment Strategy - The report recommends a portfolio of stocks including Mindray Medical, WuXi AppTec, Aier Eye Hospital, and others, focusing on companies with strong growth potential in the innovative drug sector [42][43].

Investment Rating - The report maintains an "Outperform" rating for the pharmaceutical and biotechnology sector [5] Core Views - The pharmaceutical sector underperformed the overall market, with a 0.39% decline in the biopharmaceutical sector compared to a 1.17% increase in the total A-share market [32] - The TTM price-to-earnings ratio for the pharmaceutical sector is 38.51x, which is at the 84.35th percentile of the historical valuation over the past five years [32][37] - The report highlights a shift in fund holdings, with a decrease in the proportion of pharmaceutical holdings in both pharmaceutical and non-pharmaceutical funds [11][16] Summary by Sections Market Performance - The overall A-share market increased by 1.17%, while the Shanghai and Shenzhen 300 index decreased by 0.62% [32] - The biopharmaceutical sector's performance was weaker than the overall market, with specific declines in chemical pharmaceuticals (-1.11%) and medical services (-2.17%) [32] Fund Holdings Analysis - As of Q4 2025, the net asset value of pharmaceutical funds reached 358.4 billion, a decrease of 9.0% from the previous quarter [11] - The proportion of pharmaceutical holdings in all funds was 7.97%, down 1.71 percentage points [16] - The largest sub-sectors by holdings were chemical preparations (37.5%) and other biological products (20.8%) [19] Company Earnings Forecasts and Ratings - Key companies such as Mindray Medical (237 billion market cap, "Outperform" rating) and WuXi AppTec (293.6 billion market cap, "Outperform" rating) are highlighted for their strong earnings forecasts [4] - The report lists several companies with projected earnings growth, including Aier Eye Hospital and New Industry, both rated "Outperform" [4] Investment Strategy - The report recommends focusing on innovative drugs and the CXO sector, emphasizing the competitive advantages of Chinese companies in the chemical CDMO space [41] - A portfolio of recommended stocks includes Mindray Medical, WuXi AppTec, and Aier Eye Hospital, among others [42][43]

证券研究报告 | 2026年01月26日 美元债双周报（26 年第 4 周） 弱于大市 地缘风险与财政隐忧下美债利率升至半年新高 美国 11 月 PCE 物价指数符合预期，通胀温和且支出稳健。1 月 22 日美国经 济分析局发布的 11 月 PCE 报告显示，PCE 物价指数同比上涨 2.8%，环 比上涨 0.2%，均与市场预期一致，反映通胀温和运行。剔除食品和能源 后的核心 PCE 同比亦上涨 2.8%，环比增长 0.2%，同样符合预期。报告 同时指出，美国个人支出在 11 月保持稳健增长，显示消费者支出依然 是经济增长的重要支撑，不过储蓄率进一步下滑，这或对中长期消费动 力构成一定压力。核心 PCE 维持在较高水平但未显著超预期，表明通胀 压力虽有所缓解但仍高于美联储 2%的长期目标。 2025 年第三季度美国实际 GDP 终值年化季环比增速上修至 4.4%，略超预期， 达两年最快。增长由出口增强、库存变化负面影响减小及消费韧性驱动， 表明经济扩张动力强。同期核心 PCE 终值维持在 2.9%，高于美联储 2% 目标，通胀具粘性。强劲增长与稳健就业使市场预计美联储 1 月将按兵 不动。CME 美联储观察工 ...

Investment Rating - The investment rating for the company is "Outperform the Market" (maintained) [2][3] Core Views - The company is expanding its production capacity to solidify its growth prospects, particularly in the wind power gearbox sector, aligning with the industry's trend towards larger and offshore wind power systems [3][4] - The company has a robust order backlog, with nearly 2,000 units valued at 3.037 billion yuan as of the end of 2024, representing a year-on-year increase of 100% [4][5] - The company is expected to achieve significant revenue growth, with profit forecasts for 2025-2027 at 827 million, 1.066 billion, and 1.328 billion yuan, reflecting year-on-year growth rates of 55.0%, 28.9%, and 24.5% respectively [3][6] Summary by Sections Company Overview - The company signed an investment cooperation agreement for a 10 MW wind power gearbox project, with a total investment of 5 billion yuan, aimed at meeting the demand for high-power wind turbines [3][6] - The company is actively expanding its production capacity to meet the increasing demand from downstream customers, with projects including an annual production of 1,000 units of 8 MW and 800 units of offshore wind gearboxes [6][7] Order Backlog - The company has secured framework agreements with major clients such as Goldwind Technology and Electric Wind Power, ensuring stable sales of its products [4][5] - As of May 2025, the company’s order backlog exceeded 2,800 units, setting a new record [4] Financial Projections - The company’s projected earnings for 2025-2027 are 827 million, 1.066 billion, and 1.328 billion yuan, with corresponding price-to-earnings ratios of 34.8, 27.0, and 21.7 times [3][6] - The company is expected to maintain a strong revenue growth trajectory, with a forecasted revenue of 5.489 billion yuan in 2025, up from 4.442 billion yuan in 2023 [10]